215364-85-5

Basic information

• Product Name: 4-AMINO-3-BROMO-2-CHLOROPYRIDINE
• Synonyms: 4-AMINO-3-BROMO-2-CHLOROPYRIDINE;3-Bromo-2-chloro-4-pyridinamine;4-AMino-3-broMo-2-chloropyridine, 97+%;3-broMo-2-chloropyridin-4-aMine;3-BroMo-2-chloro-pyridin-4-ylaMine;4-PyridinaMine,3-broMo-2-chloro-;SA037434
• CAS NO: 215364-85-5
• Molecular Formula: C₅H₄BrClN₂
• Molecular Weight: 207.45566
• EINECS: 1312995-182-4
• Product Categories: Pyridine;Boronic Acid;Heterocycle-Pyridine series
• Mol File: 215364-85-5.mol
• Article Data: 6

Chemical Properties

• Melting Point: 150-151°
• Boiling Point: 329 °C at 760 mmHg
• Flash Point: 152.8 °C
• Appearance: /
• Density: 1.834 g/cm³
• Vapor Pressure: 0.000183mmHg at 25°C
• Refractive Index: 1.648
• Storage Temp.: 2-8°C
• PKA: 2.73±0.42(Predicted)
• Sensitive: Air Sensitive
• CAS DataBase Reference: 4-AMINO-3-BROMO-2-CHLOROPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-AMINO-3-BROMO-2-CHLOROPYRIDINE(215364-85-5)
• EPA Substance Registry System: 4-AMINO-3-BROMO-2-CHLOROPYRIDINE(215364-85-5)

Safety Data

• Hazard Codes: T
• Statements: 25-37/38-41
• Safety Statements: 26-39-45
• RIDADR: UN 2811 6.1 / PGIII
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 215364-85-5(Hazardous Substances Data)

Usage

General Description

4-Amino-3-Brom-2-Chlorpyridin, also known as 4-Amino-3-bromo-2-chloropyridine, is a halogenated pyridine which exhibits properties attributed to its specific chemical structure, which includes both bromine and chlorine atoms along with an amino group attached to a pyridine nucleus. This organic compound is widely used as a building block in pharmaceutical and agrochemical syntheses. The beneficial properties of these compounds make them an integral part of the preparation of various biologically active substances. However, like many chemicals, handling and exposure to it should be carried out under controlled conditions to minimize health risks as it's harmful if swallowed, inhaled, or comes into contact with skin.

InChI:InChI=1/C5H4BrClN2/c6-4-3(8)1-2-9-5(4)7/h1-2H,(H2,8,9)

Upstream product

• 14432-12-3 4-Amino-2-chloropyridine 

Downstream Products

• 1268521-33-0 3-bromo-2-chloro-5-nitro-pyridin-4-ylamine 
• 850180-82-4 3-bromo-2,4-dichloro-5-nitro-pyridine 
• 1418199-28-6 C₁₄H₁₇N₅ 
• 952138-18-0 7-methoxy-1,4-dihydro-1,6-naphthyridin-4-one 
• 952138-17-9 8-bromo-7-methoxy-1,4-dihydro-1,6-naphthyridin-4-one 
• 952138-19-1 4-chloro-7-methoxy-[1,6]naphthyridine 

Relevant articles and documents

GDF-8 INHIBITORS

Disclosed are 2,2'-bipyridyl compounds, as well as pharmaceutical compositions and methods of use thereof. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein R1, Z and n are as described herein. In certain embodiments, a compound disclosed herein inhibits GDF8, and can be used to treat disease by blocking GDF8 signaling.

Aurora Kinase Modulators and Method of Use

The present invention relates to chemical compounds having a general formula I wherein A1-8, D′, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.

AURORA KINASE MODULATORS AND METHOD OF USE

The present invention relates to chemical compounds having a general formula I {INSERT STRUCTURE HERE} wherein A1-8, D,, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.